Shares of Lupin slipped more than 2 percent in the early trade on Monday after Credit Suisse highlighted concerns over the volume loss in its diabetes franchise. The brokerage sees a downside of 9 percent on the stock.
Credit Suisse has maintained its neutral stance on the stock with a target cut to Rs 770 from Rs 850, implying a downside of over 9 percent.
It said that there is massive volume loss in diabetes franchise in the US and has cut earnings and target.
Credit Suisse has maintained its neutral stance on the stock with a target cut to Rs 770 from Rs 850, implying a downside of over 9 percent.
It said that there is massive volume loss in diabetes franchise in the US and has cut earnings and target.
For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory
No comments:
Post a Comment